retatrutide clinical trial results weight loss VisualAbstract: reduces body by 17.5% in patients with obesity Dr. Tara Narula breaks down

These products are not FDA-approved to diagnose, treat, cure, or prevent any disease

This may affect medications with a narrow therapeutic index, so monitoring may be required

Approximately 20% of patients will not respond to LDN

Severe pelvic pain is a common symptom

Rural and semi-urban areas may have sporadic availability, long travel distances to specialists, and limited awareness among general practitioners.[6] 5.2 Off-Label Use and Regulatory Grey Areas Social media has popularised GLP-1 as a weight-loss injection even for people without diabetes or clinical obesity

The FDA lists these along with vomiting, constipation, and abdominal pain as expected reactions